福瑞达: 鲁商福瑞达医药股份有限公司第十二届董事会第六次会议决议公告

Core Viewpoint - The board of directors of Lushang Furuida Pharmaceutical Co., Ltd. held its sixth meeting of the twelfth session, where several key resolutions were passed regarding the company's financial report, action plans, risk assessments, and governance structure [1][2][3][4] Group 1: Financial and Operational Reports - The board unanimously approved the "2025 Semi-Annual Report" which reflects the company's financial status and operational results for the first half of 2025 [1] - The board also approved the "Semi-Annual Evaluation Report on the 'Quality Improvement and Efficiency Enhancement Return' Action Plan" [2] Group 2: Governance and Structural Changes - The board approved a proposal to cancel the supervisory board and amend the company's articles of association, allowing the audit committee to assume the supervisory functions [3] - A resolution was passed to revise and establish certain governance systems in accordance with relevant laws and regulations, reflecting the changes in the company's governance structure [4] - The board appointed Dou Qianqian as the company secretary, with her term aligned with the current board's term [2]